CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that the Swiss regulatory body, Swissmedic, has approved the use of platelet components treated with Cerus’ INTERCEPT Blood System. The approval extends permitted storage time for platelets to seven days with INTERCEPT treatment, compared to five days without treatment.
